Insurance denial rates for direct-acting antiviral drugs used to treat hepatitis C are high—more than 50% for those with private insurance—according to a study in Open Forum Infectious Diseases. The drugs have been a game-changer in saving patients lives.
Read more via Penn Medicine News and access the study at Oxford Academic.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
